Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
2011
Findings offer mechanistic and pharmacologic information that significantly advances understanding of the biology and therapeutic utility of ALK1 antibodies for cancer treatment.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
45
References
104
Citations
NaN
KQI